BCAIX | VTISX | BCAIX / VTISX | |
Total Expense Ratio | 0.88 | 0.05 | 1,872% |
Annual Report Gross Expense Ratio | 1.02 | 0.05 | 2,170% |
Fund Existence | 15 years | 9 years | - |
Gain YTD | 18.519 | 19.807 | 93% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 10000 | 3000000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 311M | 511B | 0% |
Annual Yield % from dividends | 2.34 | 2.85 | 82% |
Returns for 1 year | 13.43 | 17.74 | 76% |
Returns for 3 years | 34.95 | 40.29 | 87% |
Returns for 5 years | 23.46 | 42.45 | 55% |
Returns for 10 years | 49.97 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ASVDX | 10.25 | 0.07 | +0.69% |
American Century Small Cap Value R6 | |||
GSLLX | 23.27 | 0.09 | +0.39% |
Goldman Sachs Enhanced U.S. Equity Inv | |||
PGICX | 18.74 | 0.06 | +0.32% |
Virtus KAR Equity Income C | |||
FBTAX | 28.16 | 0.01 | +0.04% |
Fidelity Advisor Biotechnology A | |||
NZDCNY | 4.32 | N/A | N/A |
New Zealand Dollar - China Yuan |